海思科：获得创新药HSK44459片新适应症IND申请《受理通知书》

Core Insights - Company Haikang obtained the IND application acceptance notice for its innovative drug HSK44459, targeting inflammatory bowel disease [1] - The company reported a net profit attributable to shareholders of 166 million yuan for Q3 2025, representing a year-on-year decline of 23.32% [1] Company Summary - Haikang's new drug HSK44459 has received approval for a new indication, which is inflammatory bowel disease [1] - The financial performance for Q3 2025 shows a significant decrease in net profit compared to the same period last year [1]